A recent Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. patent describes new 4-substituted fused bicyclic heteroaryl derivatives acting as Kelch-like ECH-associated protein 1 (Keap1)/CUL3 interaction inducers reported to be useful for the treatment of cancer.
Jiangxi Kerui Pharmaceutical Co. Ltd. has reported new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of acute pain.
Shenzhen Targetrx Inc. has patented proteolysis targeting chimeras (PROTACs) comprising cereblon ligands coupled to a hepatocyte growth factor receptor (HGFR, MET)-targeting moiety via linker acting as HGFR degradation inducers potentially useful for the treatment of cancer.
Shanghai Escugen Biotechnology Co. Ltd. has disclosed new antibody-drug conjugates comprising chimeric monoclonal antibodies targeting CD174 (Lewis y) covalently linked to a cytotoxic drug. They are potentially useful for the treatment of cancer.
Work at Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has led to the identification of new gadolinium complexes reported to be potentially useful as magnetic resonance imaging (MRI) contrast agents.
Shijiazhuang Yiling Pharmaceutical Co. Ltd. has divulged new lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists potentially useful for the treatment of pulmonary fibrosis.
After languishing on the U.S. Senate floor for more than a year, the Affordable Prescriptions for Patients Act (S. 1041) finally got a unanimous vote July 21 and is now on its way to the House, again. Aimed at reining in patent thickets, the bill limits the number of patents a biologics sponsor can assert against a biosimilar when engaging in the voluntary “patent dance” laid out in the Biologics Price Competition and Innovation Act. The number is no more than 20 patents, a limit the bill’s bipartisan sponsors called “reasonable.”
Tianjin Tianyao Pharmaceuticals Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of systemic inflammatory response syndrome (SIRS), autoimmune disease, lung and kidney injury and sepsis.
Changchun Genescience Pharmaceuticals Co. Ltd. has described a prodrug and its antibody-drug conjugates with a controllable drug release rate found to be potentially useful for the treatment of hyperparathyroidism.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has patented integrin α4β7 (LPAM-1) antagonists that are potentially useful for the treatment of autoimmune disease, ulcerative colitis and Crohn’s disease.
RSS
